NL7503788A - Werkwijze voor de bereiding van 16-methyl- -9(alpha)-halogeensteroidesters en -ethers met farmacologische werking. - Google Patents

Werkwijze voor de bereiding van 16-methyl- -9(alpha)-halogeensteroidesters en -ethers met farmacologische werking.

Info

Publication number
NL7503788A
NL7503788A NL7503788A NL7503788A NL7503788A NL 7503788 A NL7503788 A NL 7503788A NL 7503788 A NL7503788 A NL 7503788A NL 7503788 A NL7503788 A NL 7503788A NL 7503788 A NL7503788 A NL 7503788A
Authority
NL
Netherlands
Prior art keywords
ethers
alpha
methyl
preparation
pharmacological action
Prior art date
Application number
NL7503788A
Other languages
English (en)
Other versions
NL184321B (nl
NL184321C (nl
Original Assignee
Plurichemie Anstalt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Plurichemie Anstalt filed Critical Plurichemie Anstalt
Publication of NL7503788A publication Critical patent/NL7503788A/nl
Publication of NL184321B publication Critical patent/NL184321B/nl
Application granted granted Critical
Publication of NL184321C publication Critical patent/NL184321C/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J7/00Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C07J7/0055Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J5/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C07J5/0046Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa
    • C07J5/0061Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16
    • C07J5/0069Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group
    • C07J5/0076Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond substituted in position 17 alfa substituted in position 16 by a saturated or unsaturated hydrocarbon group by an alkyl group

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NLAANVRAGE7503788,A 1974-03-27 1975-03-27 Werkwijze voor de bereiding van steroiden. NL184321C (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT6163674 1974-03-27
PT6163774 1974-03-27

Publications (3)

Publication Number Publication Date
NL7503788A true NL7503788A (nl) 1975-09-30
NL184321B NL184321B (nl) 1989-01-16
NL184321C NL184321C (nl) 1989-06-16

Family

ID=26653426

Family Applications (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7503788,A NL184321C (nl) 1974-03-27 1975-03-27 Werkwijze voor de bereiding van steroiden.

Country Status (9)

Country Link
US (1) US4024131A (nl)
JP (2) JPS6043358B2 (nl)
AU (1) AU500060B2 (nl)
CA (1) CA1065848A (nl)
DE (1) DE2512915A1 (nl)
HK (2) HK64779A (nl)
NL (1) NL184321C (nl)
PH (1) PH13537A (nl)
SE (1) SE418294B (nl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201778A (en) * 1977-11-08 1980-05-06 Schering Corporation 6-Acyloxy-1,4,6-pregnatrienes, their use as anti-inflammatory agents, methods for their manufacture, and 6-oxo-1,4-pregnadiene intermediates
DE3071122D1 (en) * 1979-11-16 1985-10-31 Sterosynt Ltd 6-alpha-fluoro-9-alpha-chloro-prednisolone-17,21 diesters, pharmaceutical compositions containing them and intermediates
PT71309A (en) * 1980-05-27 1980-06-01 Hovione Sociedade Quimica Lda Process of selective
IL66432A0 (en) * 1981-08-04 1982-12-31 Plurichemie Anstalt Process for the preparation of steroidal esters
PT78973A (en) * 1984-07-25 1984-08-01 Joao Emerico Villax New preparation process of the 9alpha-fluoro 17,21-acylates or hidroxilades in 17 and 21 chloro-corticosteroid
JPS62111184U (nl) * 1985-12-29 1987-07-15
JPH07116215B2 (ja) * 1989-04-19 1995-12-13 エスエス製薬株式会社 新規なステロイド化合物
WO2002051422A1 (fr) * 2000-12-22 2002-07-04 Ssp Co., Ltd. Agents preventifs/remedes destines a des maladies inflammatoires des voies aeriennes
CN104558083B (zh) * 2013-10-16 2018-08-31 天津金耀集团有限公司 一种倍氯米松双丙酸酯无有机溶剂的合成方法
CN104558082B (zh) * 2013-10-16 2018-01-23 天津金耀集团有限公司 一种倍氯米松双丙酸酯的合成方法
CN111944002A (zh) * 2020-07-29 2020-11-17 河南利华制药有限公司 一种倍氯米松二丙酸酯中间体及制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047518A (en) * 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡-monoesters of 11,17,21-trihydroxy steroid compounds
GB1070751A (en) * 1964-01-28 1967-06-01 Glaxo Lab Ltd 17-esters of 17-hydroxy-21-desoxy-steroids
NL6612191A (nl) * 1965-08-30 1967-03-01
US3639434A (en) * 1967-02-02 1972-02-01 Boots Pure Drug Co Ltd 17-acyloxysteroids and their manufacture
CH534144A (de) * 1967-11-17 1973-02-28 Ciba Geigy Ag Verfahren zur Herstellung neuer Halogenpregnadiene
GB1227992A (nl) * 1968-01-23 1971-04-15 Koninklijke Gist Spiritus
GB1281689A (en) * 1968-10-14 1972-07-12 Glaxo Lab Ltd Steroid 21-phosphates
BE785812A (fr) * 1971-07-05 1973-01-04 Glaxo Lab Ltd Nouveaux composes steroides

Also Published As

Publication number Publication date
JPS6241680B2 (nl) 1987-09-03
JPS58189200A (ja) 1983-11-04
JPS6043358B2 (ja) 1985-09-27
US4024131A (en) 1977-05-17
PH13537A (en) 1980-06-19
DE2512915A1 (de) 1975-10-09
HK64679A (en) 1979-09-21
AU7960375A (en) 1976-09-30
JPS50157353A (nl) 1975-12-19
SE7503356L (nl) 1975-09-28
NL184321B (nl) 1989-01-16
HK64779A (en) 1979-09-21
NL184321C (nl) 1989-06-16
DE2512915C2 (nl) 1987-09-10
SE418294B (sv) 1981-05-18
CA1065848A (en) 1979-11-06
AU500060B2 (en) 1979-05-10

Similar Documents

Publication Publication Date Title
NL7414283A (nl) Werkwijze voor de bereiding van silanen.
NL7510225A (nl) Werkwijze voor de bereiding van nieuwe steroiden uit de androstaanreeks.
NL7503513A (nl) Werkwijze voor de bereiding van 7(beta)-acylamino- -7(alpha)-alkoxycefalosporinen en 6(beta)-acylamino-6ã(alpha)-al- koxypenicillinen.
NL7512759A (nl) Werkwijze voor de bereiding van hydroxypivaldehyde.
NL7502504A (nl) Werkwijze voor de bereiding van een etheen-(alpha)-al- keencopolymeer.
NL7514696A (nl) Werkwijze voor de bereiding van nieuwe gesubsti- tueerde propaan-2-ol derivaten en nicotinezure ester daarvan.
NL7610812A (nl) Werkwijze ter bereiding van farmaceutische pre- paraten met erythropoesewerking en nieuwe steroiden voor toepassing in dergelijke prepa- raten.
NL7503788A (nl) Werkwijze voor de bereiding van 16-methyl- -9(alpha)-halogeensteroidesters en -ethers met farmacologische werking.
NL7505008A (nl) Werkwijze voor het bereiden van (alpha).(beta)-onverzadigde aldehyden.
NL153205B (nl) Werkwijze voor de bereiding van organotintrihalogeniden.
NL165931C (nl) Werkwijze voor de bereiding van tabletten of supposi- toria met anti-arteriosclerotische werking en aldus verkregen tabletten of suppositoria.
NL7509980A (nl) Werkwijze voor de bereiding van 7(beta)-acylamino- -7(alpha)-alkoxycefalosporinen.
NL7603449A (nl) Werkwijze voor de bereiding van (alpha)-fenylpropion- zuren.
NL7505835A (nl) Werkwijze voor de bereiding van epoxyden uit vinylesters.
NL7513392A (nl) Werkwijze voor de bereiding van nieuwe steroiden.
NL7505461A (nl) Werkwijze voor de bereiding van (alpha)-aminoacyl- penicilline-derivaten.
NL7511067A (nl) Werkwijze voor de bereiding van orgoteinederi- vaten.
NL7500686A (nl) Werkwijze voor de bereiding van cyclopentaan- dionen.
NL7502287A (nl) Werkwijze voor de bereiding van esters.
NL7612626A (nl) Werkwijze voor de bereiding van 3-alkoxybuteen- -1 en alkyl-trans-butenylether.
NL301985A (nl) Werkwijze voor de bereiding van azijnzuur en butylacetaat
NL7506166A (nl) Sulfonzuurderivaten met de structuur van polyoxapolyfluoralkanen en werkwijze voor de bereiding daarvan.
NL7501218A (nl) Werkwijze ter bereiding van preparaten met her- e eigenschappen.
NL7504608A (nl) Werkwijze voor de bereiding van 3-hemi-natrium- sulfaten van 17(alpha)-hydroxy-steroiden.
NL7503746A (nl) Werkwijze voor de bereiding van 2-nitrobenzal- dehyde.

Legal Events

Date Code Title Description
BA A request for search or an international-type search has been filed
BB A search report has been drawn up
BC A request for examination has been filed
A85 Still pending on 85-01-01
V4 Discontinued because of reaching the maximum lifetime of a patent